Eli Lilly's antibody drug bamlanivimab was found to "significantly" reduce the risk of contracting symptomatic COVID-19 in nursing homes, the company has announced.
Eli Lilly said Thursday a phase 3 trial showed that nursing home residents who preventively received bamlanivimab rather than a placebo had an up to 80 percent lower risk of contracting symptomatic COVID-19. Additionally, the company said bamlanivimab reduced the risk by 57 percent for both residents and staff, The Wall Street Journal reports.
"We are exceptionally pleased with these positive results, which showed bamlanivimab was able to help prevent COVID-19, substantially reducing symptomatic disease among nursing home residents, some of the most vulnerable members of our society," Eli Lilly chief scientific officer Daniel Skovronsky said.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Skovronsky further explained in an interview with the Journal that the company's antibody treatment is "not an alternative for a vaccine," but "for people who haven't been vaccinated, and there's an outbreak in their facility — this could be a last resort." In Eli Lilly's announcement, Skovronsky said that after the Food and Drug Administration previously provided an emergency use authorization for bamlanivimab, the company hopes to work "with regulators to explore expanding the emergency use authorization to prevent the spread of COVID-19 in these facilities."
-
Trump, Putin set summit as Zelenskyy lands in DCSpeed Read Trump and Putin have agreed to meet in Budapest soon to discuss ending the war in Ukraine
-
Doctors sound the alarm about insurance company ‘downcoding’The Explainer ‘It’s blatantly disrespectful,’ one doctor said
-
Courts deal setbacks to Trump’s Chicago operationsSpeed Read President Donald Trump cannot deploy the National Guard in Illinois
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panelspeed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
